Astellas Gene Therapy Deal History & Licensing Activity
Astellas Gene Therapy is a large pharma headquartered in Japan. Over the past three years, Astellas Gene Therapy has been involved in 1 licensing and acquisition transaction, with a primary focus on Bispecific Antibodies (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
Astellas Gene Therapy Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Astellas Gene Therapy in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| VIR-5500 | Astellas | Bispecific Antibodies | Unknown | collaboration | Mar 2026 |
Astellas Gene Therapy Pipeline Focus
Therapeutic areas and modalities where Astellas Gene Therapy is most active based on deal history and clinical trial data.
Therapeutic Areas
Astellas Gene Therapy Strategic Signals
Key indicators of Astellas Gene Therapy's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Astellas Gene Therapy Clinical Pipeline
Astellas Gene Therapy has 50 active clinical trials across 6 development phases.
9
Unknown
1
Not Applicable
2
Phase 4
16
Phase 1
15
Phase 2
7
Phase 3
See How Your Asset Matches Astellas Gene Therapy's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Astellas Gene Therapy Licensing & Deal Activity
Astellas Gene Therapy is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Astellas Gene Therapy ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Astellas Gene Therapy include Solid Tumors (29 deals and trials), Hematological Malignancies (3 deals and trials), Oncology (2 deals and trials), and CNS Disorders (1 deal and trial). In terms of modality, Astellas Gene Therapy has shown particular interest in bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Astellas Gene Therapy and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Astellas Gene Therapy's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.